DOI:
10.1055/s-00000017
Experimental and Clinical Endocrinology & Diabetes
LinksClose Window
References
Courtney KD, Infante JR, Lam ET. et al.
Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma.
J Clin Oncol 2018;
36: 867-874
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.